FNBT
AVEO

FineMark National Bank & Trust’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

FineMark National Bank & Trust’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,000
Closed -$90K – 430
2018
Q2 		$90K Buy
4,000
+2,000
+100% +$47.4K 0.01% 395
2018
Q1 		$58K Buy
2,000
+1,000
+100% +$29.3K ﹤0.01% 387
2017
Q4 		$28K Buy
+1,000
New +$31K ﹤0.01% 365

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FineMark National Bank & Trust's AVEO Position: Q3 2018 in Review

FineMark National Bank & Trust sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2018, closing a stake of 4,000 shares — an estimated $90K sold.

FineMark National Bank & Trust first reported a position in AVEO in Q4 2017 and held it in 3 quarters. The position peaked at $90K in Q2 2018. 101 funds tracked by Wall St. Rank hold AVEO as of Q3 2018.

  • FineMark National Bank & Trust reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • FineMark National Bank & Trust sold 4,000 AVEO Pharmaceuticals, Inc. shares in Q3 2018, an estimated $90K.
  • FineMark National Bank & Trust first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • FineMark National Bank & Trust's AVEO Pharmaceuticals, Inc. position peaked at $90K in Q2 2018.
  • 101 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2018.

Based on FineMark National Bank & Trust's 13F filing for Q3 2018, filed 2 Nov 2018.